A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers

Human Psychopharmacology

Volumn 32, Issue 1, 2017, Pages

  Boland, Katja ^a   Moschetti, Viktoria ^a   Dansirikul, Chantaratsamon ^a   Pichereau, Solen ^a   Gheyle, Lien ^b   Runge, Frank ^a   Zimdahl Gelling, Heike ^a   Sand, Michael ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b Life Science Services Biometrics   (Belgium)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Alzheimer disease; cGMP; PDE inhibitor; PDE9A; schizophrenia

Indexed keywords

BI 409306; CYCLIC GMP; PHOSPHODIESTERASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; CYCLIC AMP PHOSPHODIESTERASE; PDE9A PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; BLURRED VISION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID-TO-PLASMA RATIO; COLOR VISION; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LIMB PAIN; LUMBAR PUNCTURE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; POST LUMBAR PUNCTURE SYNDROME; PRESSURE SENSATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROOF OF CONCEPT; YOUNG ADULT;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROOF OF CONCEPT STUDY; YOUNG ADULT;

EID: 85010635574     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2569     Document Type: Article

References (23)

1. Bonkale, W. L., Winblad, B., Ravid, R., & Cowburn, R. F. (1995). Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neuroscience Letters, 187(1), 5–8.
2. Brown, D., Daniels, K., Zhang, S., Pichereau, S., & Sand, M. (2015). Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 409306 filmcoated tablets given orally qd for 14 days in patients with schizophrenia. International Congress on Schizophrenia Research. Schizophrenia Bulletin, 41(suppl 1), S304.
3. Dorner-Ciossek, C., Giovannini, R., & Rosenbrock, H. (2015). BI 409306, a novel phosphodiesterase 9A inhibitor, part I: Potency, selectivity and in-vitro functional characterization on synaptic plasticity. International Congress on Schizophrenia Research. Schizophrenia Bulletin, 41(suppl 1), S31.
4. García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarzábal, J., & Franco, R. (2012). Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chemical Neuroscience, 3(11), 832–844.
5. Gattaz, W. F., Cramer, H., & Beckmann, H. (1983). Low CSF concentrations of cyclic GMP in schizophrenia. The British Journal of Psychiatry, 142, 288–291.
6. Holder, S. D., & Wayhs, A. (2014). Schizophrenia. American Family Physician, 90(11), 775–782.
7. Keefe, R. S., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far? Schizophrenia Bulletin, 39(2), 417–435.
8. Kitchen, H., Rofail, D., Heron, L., & Sacco, P. (2012). Cognitive impairment associated with schizophrenia: A review of the humanistic burden. Advances in Therapy, 29(2), 148–162.
9. Kleiman, R. J., Chapin, D. S., Christoffersen, C., Freeman, J., Fonseca, K. R., Geoghegan, K. F., … Schmidt, C. J. (2012). Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. The Journal of Pharmacology and Experimental Therapeutics, 341(2), 396–409.
10. Lewis, D. A., & Moghaddam, B. (2006). Cognitive dysfunction in schizophrenia: Convergence of gamma–aminobutyric acid and glutamate alterations. Archives of Neurology, 63(10), 1372–1376.
11. Millier, A., Schmidt, U., Angermeyer, M. C., Chauhan, D., Murthy, V., Toumi, M., & Cadi-Soussi, N. (2014). Humanistic burden in schizophrenia: A literature review. Journal of Psychiatric Research, 54, 85–93.
12. Morris, J. C., Blennow, K., Froelich, L., Nordberg, A., Soininen, H., Waldemar, G., … Dubois, B. (2014). Harmonized diagnostic criteria for Alzheimer's disease: Recommendations. Journal of Internal Medicine, 275(3), 204–213.
13. Moschetti, V., Boland, K., Feifel, U., Hoch, A., Zimdahl-Gelling, H., & Sand, M. (2016). First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males. British Journal of Clinical Pharmacology, 82(5), 1315–1324.
14. Moschetti, V., Boland, K., Hoch, A., Timmer, W., Zimdahl-Gelling, H., Borta, A., & Sand, M. (2015). Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of BI 409306 film-coated tablets given orally once or twice daily for 14 days in young and elderly healthy volunteers. Poster presented at the Alzheimer's Association International Conference, Washington, DC, USA, July 18–23, 2015.
15. Nicholas, T., Evans, R., Styren, S., Qiu, R., Wang, E. Q., Nelson, F., … Soares, H. (2009). PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers. Alzheimer's & Dementia, 5(4) : suppl, P330–P331.
16. Reneerkens, O. A., Rutten, K., Steinbusch, H. W., Blokland, A., & Prickaerts, J. (2009). Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology, 202(1–3), 419–443.
17. Reyes-Irisarri, E., Markerink-Van Ittersum, M., Mengod, G., & de Vente, J. (2007). Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. The European Journal of Neuroscience, 25(11), 3332–3338.
18. Rosenbrock, H., Marti, A., Koros, E., Runge, F., Fuchs, H., Giovannini, R., & Dorner-Ciossek, C. (2015). BI 409306, a novel phosphodiesterase 9A inhibitor, part II: In-vivo characterization regarding target engagement and cognition tasks in rodents. International Congress on Schizophrenia Research. Schizophrenia Bulletin, 41(suppl 1), S36–S37.
19. Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2012). New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease modifying drugs. British Journal of Clinical Pharmacology, 73(4), 504–517.
20. Schmidt, C. J. (2010). Phosphodiesterase inhibitors as potential cognition enhancing agents. Current Topics in Medicinal Chemistry, 10(2), 222–230.
21. Schmidt, C.J., Harms, J.F,, Tingley, F.D., Schmidt, K., Adamowicz, W.O., Romegialli, A., … Stephenson, D.T. (2009). PDE9A-mediated regulation of cGMP: Developing a biomarker for a novel therapy for Alzheimer's disease. Poster presented at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease.
22. Ugarte, A., Gil-Bea, F., García-Barroso, C., Cedazo-Minguez, Á., Ramirez, M. J., Franco, R., … Cuadrado-Tejedor, M. (2015). Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathology and Applied Neurobiology, 41(4), 471–482.
23. Wunderlich, G., Timmer, W., Andersen, G., Hoch, A., Moschetti, V., Boland, K., Sand, M., (2015). Two phase I studies evaluating the safety, tolerability, and pharmacokinetics of multiple rising doses of BI 409306 in young and elderly healthy volunteers. Presented at the 8th Clinical Trials on Alzheimer's (CTAD) Conference, Barcelona, Spain. November 5–7, 2015.